HIGHLIGHTS
- who: Anna Wolska-Washer and Tadeusz Robak from the The Ohio State University, United States have published the paper: Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions, in the Journal: (JOURNAL)
- what: The primary reason for treatment discontinuation was disease progression (31.3%) and adverse events (AEs; 25%). The main reasons were progressive disease (46%) and AEs (15.4%). This study showed potential in the tailoring of the combined targeted treatment based on the results of the mutational status in the signaling pathways in the tumor cells. The study was retrospective . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.